The potential for HIV preexposure prophylaxis (PrEP) to reduce the racial disparities in HIV incidence in the United States may be limited by racial gaps in PrEP care. We used a network-based mathematical model of HIV transmission for younger black and white men who have sex with men (B/WMSM) in the Atlanta area to evaluate how race-stratified transitions through the PrEP care continuum from initiation to adherence and retention could impact HIV incidence overall and disparities in incidence between races, using current empirical estimates of BMSM continuum parameters. Relative to a no-PrEP scenario, implementing PrEP according to observed BMSM parameters was projected to yield a 23% decline in HIV incidence (HR = 0.77) among BMSM at year 10. The racial disparity in incidence in this observed scenario was 4.95 per 100 person-years at risk (PYAR), a 19% decline from the 6.08 per 100 PYAR disparity in the no-PrEP scenario. If BMSM parameters were increased to WMSM values, incidence would decline by 47% (HR = 0.53), with an associated disparity of 3.30 per 100 PYAR (a 46% decline in the disparity). PrEP could simultaneously lower HIV incidence overall and reduce racial disparities despite current gaps in PrEP care. Interventions addressing these gaps will be needed to substantially decrease disparities.
potential impact of PrEP for MSM across races (26, 27) . This study integrated these two research streams to develop the model structure, parameterization, and analyses for simulating PrEP stratified by race and represent PrEP care on a continuum framework. Full methodological details are provided in an Appendix.
HIV Transmission and Progression. Our model simulates the dynamics of main, casual, and one-time sexual partnerships for non-Hispanic BMSM and WMSM, aged 18-40 (26,27) . Predictors of partnership formation included partnership type, number of ongoing partnerships, race and age mixing, and sorting by receptive versus insertive sexual position. For main and casual partnerships, we modeled relational dissolution as a constant hazard reflecting their median durations. All network model terms were stratified by race.
MSM progressed through HIV disease in the absence of antiretroviral therapy (ART) with evolving HIV viral loads that modified the rate of HIV transmission (28) . After infection, men were assigned into clinical care trajectories controlling rates of HIV diagnosis, ART initiation, and HIV viral suppression (29, 30) . ART was associated with decreased mortality and lower HIV transmissibility (31) . Other factors modifying the HIV acquisition probability included current infection with other sexually transmitted infections (32) , condom use (33) , sexual position (34) , and circumcision of the insertive partner (35) .
Parameters for network/behavioral features of the model were estimated from two studies of HIV disparities between younger BMSM and WMSM in Atlanta, our target population (22, 36) . Involvement was a prospective HIV incidence cohort (n=803) and the MAN Project was a cross-sectional chain-referral sexual network study (n = 314). Venue-time-space sampling was used for both studies to minimize selection biases. Remaining model parameters for the underlying model (e.g., HIV natural history and ART clinical effects) were assumed to be common across MSM populations and therefore drawn from secondary literature sources. Methods for data analysis and assumptions for model parameterization are described in greater detail in the Appendix and Goodreau et al. (26) .
PrEP Continuum. We represented PrEP based on a five-step continuum: awareness of PrEP, access to healthcare, likelihood of receiving a prescription, effective adherence, and retention in care. Racestratified probabilities governing transitions across steps were drawn from two PrEP demonstration projects (11, 21) . Awareness was estimated as 50% for both races, whereas access was 76% for BMSM and 95% for WMSM. Both were fixed attributes assigned at entry into the network.
Prescription probabilities were 63% for BMSM and 73% WMSM, simulated as a Bernoulli random draw at the point of clinical evaluation for and precondition of initiating PrEP: diagnostic HIV screening.
Screening rates were stratified by race based on empirical data (see Appendix), but were assumed homogenous otherwise. Consistent with prior models (32), we simulated the four biobehavioral indications for starting PrEP defined in the CDC guidelines (37): higher-risk sexual behavior in various partnership configurations or an STI diagnosis within the prior 6 months. Because indications were time-varying, the probability of a PrEP prescription was therefore a joint function of the race-specific probability of receiving a prescription plus current indications at HIV screening.
Effective PrEP adherence in the model represented men taking 4+ doses per week across follow-up (11) . Proportions meeting this criterion were 60% for BMSM and 93% for WMSM. Taking PrEP at this dosage was been associated with a 98% relative reduction in HIV acquisition risk per sexual act, following Grant et al (38) . MSM who were adherent to PrEP at this level reduced their condom use with by 40% (39) . PrEP discontinuation (the converse of retention) rates were based on observed proportions of MSM with indications who had stopped PrEP by week 48 of follow-up (43.8% for BMSM and 18.3% for WMSM). We transformed these proportions into median times to discontinuation (1.1 years and 3.2 years, respectively) assuming a hypergeometric distribution. We simulated this form of spontaneous discontinuation conditional on having ongoing indications, consistent with our data analysis. In addition, men stopped PrEP if they no longer exhibited PrEP indications (evaluated annually for active PrEP users) (37) .
Counterfactual Scenarios. To estimate the causal impact of changes to the PrEP continuum for BMSM, we varied the probabilities for each of the five steps individually and jointly. The reference scenario to which all intervention counterfactuals were compared was that no MSM (of either race) were on PrEP.
While this scenario does not represent a proposed public health strategy, it provides maximum analytical clarity for estimating HIV disparities before and after the introduction of PrEP. Furthermore, we calibrated the model to race-stratified HIV prevalence estimates in 2013, just after the FDA approval of PrEP (37) .
For individual continuum steps, we set the parameters for BMSM to those marginal values observed for WMSM and then higher levels, while holding other BMSM continuum parameters fixed at their observed levels. The WMSM continuum and all other model parameters, including those governing risk behavior and HIV clinical care, were always held fixed across all scenarios; results here are conditional on that assumption. For scenarios modifying parameters in combination, we varied the BMSM parameters on a relative scale. Scenarios in which BMSM parameters were set to 150% of observed values, for example, multiplied each of the empirical estimates by 1.5 (with individual probabilities capped at 1). For our final analysis, we grouped the five continuum steps into two factor groups -initiation (awareness, access, and prescription) and engagement (adherence and retention) -and then projected outcomes across a spectrum of relative BMSM values in each group.
Calibration, Simulation, and Analysis. With a starting network size of 10,000 MSM (aged 18-40), 50%
were initialized in each race, a ratio that approximates the distribution for the Atlanta area and provides analytical clarity (26) . We calibrated our model to observed race-specific HIV prevalence at baseline in an Atlanta-based cohort: 43.4% for BMSM and 13.2% for WMSM (22) . Based on prior work on modeling the causes of these disparities (26) , we incorporated the full 95% confidence intervals of estimated rates of anal intercourse and probabilities of condom use for model calibration. We also implemented racespecific parameters simulating condom failure (due to slippage or breakage), consistently higher in BMSM (40) (41) (42) , and diagnostic screening for bacterial STIs (increasing the risk of HIV if untreated), often lower for BMSM (4) . Approximate Bayesian computation methods estimated the values of these parameters best fitting the observed prevalence data (32, 43 ). The calibrated model provided an excellent fit to these targets. We also successfully externally validated this calibration with an "out-of-model" prediction of HIV prevalence by the interaction of race and age (see Appendix Section 12).
Intervention models simulated each scenario over a 10-year time horizon. For each scenario, we simulated the model 250 times and summarized the distribution of results based on median values and 95% credible intervals (CrI). Outcomes were race-specific HIV prevalence and incidence per 100 person years at risk (PYAR), and the hazard ratio comparing incidence to the no-PrEP reference scenario, all at year 10. The percent of infections averted (PIA) among BMSM compared the cumulative incidence in each intervention scenario to that of the reference scenario. The number needed to treat (NNT) was the number of BMSM person-years on PrEP required to avert one new HIV infection for BMSM. Two disparity indices were calculated to compare PrEP impact for BMSM versus WMSM: the absolute disparity was the difference in incidence rates for BMSM and WMSM, and the relative disparity was the ratio of those rates.
Finally, we calculated a prevention index as the difference in hazard ratios associated with PrEP uptake for BMSM and WMSM. Table 1 shows the impact of individual PrEP continuum steps for BMSM at observed and counterfactual values. In comparison with the reference scenario in which no one (of either race) received PrEP, the observed BMSM PrEP continuum scenario projected 8.4% (CrI = 7.7, 9.1) of BMSM to be on PrEP across follow-up. This yielded a 3-percentage point decline in HIV prevalence (39.9% versus 43.1%) and a 23% decline in incidence (HR = 0.77; CrI = 0.57, 0.99) among BMSM at year 10. The cumulative PIA was 14.1% (CrI = 8.2%, 21.0%) for BMSM over the intervention horizon. We then modeled changes to individual steps (holding parameters for remaining steps at observed BMSM values). For awareness, while the observed values were equal for both races, increasing that awareness proportion for BMSM had a strong impact on PrEP use, and with that, declines in incidence. For access, setting the BMSM access parameter to the observed WMSM value (95%) resulted in a smaller decline in incidence than changes to awareness. Conditional on access, empirical differences in the probability of prescription were relatively small. Increasing the proportion highly adherent did not impact the overall proportion of BMSM on PrEP (which includes PrEP users across adherence levels); this also resulted in a relatively small prevention effect. Higher levels of retention on PrEP were associated with greater PrEP prevention benefits because fewer MSM indicated for PrEP were cycled off PrEP during their periods of high sexual risk.
RESULTS
In Table 2 , we project the impact of scaling the BMSM continuum parameters jointly on HIV incidence outcomes for both BMSM and WMSM. Compared to the scenario in which all BMSM continuum parameters were set to observed levels for BMSM, when all BMSM parameters were set to levels observed for WMSM we project that 17.7% (CrI = 16.8%, 18.7%) of BMSM would actively be on PrEP.
This compares to 23.4% (CrI = 22.4%, 24.4%) of WMSM, with the difference due to WMSM's higher level of CDC PrEP indications even when all continuum parameters were equal. In this scenario where BMSM parameters were set to observed WMSM values, incidence among BMSM would be lower (HR = 0.53 versus 0.77) than in the scenario in which BMSM parameters were set to observed BMSM values.
Scaling up BMSM continuum parameters to even higher levels (150% or 200% of observed BMSM values) would result in even greater numbers of BMSM on PrEP, with stronger incidence reductions BMSM. Overall, all levels of PrEP modeled (even those poorer than observed) resulted in a reduction in HIV incidence for BMSM compared to no PrEP, with increasing initiation and engagement associated with incidence declines by greater than three-quarters at optimistic implementation levels. The relative disparity index tells a different story. Under no PrEP, the predicted relative disparity was 4.68, whereas the disparity would increase to 6.32 in the observed BMSM scenario. Relative disparities increased despite higher PrEP use among BMSM because this relative measure is sensitive to changes in its denominator (i.e., WMSM incidence, as a function of their PrEP use). Only when the individual-level benefit of PrEP is greater for BMSM compared to WMSM (i.e., the prevention index is less than 0) do the relative disparities fall below levels in the no-PrEP scenario. Overall levels of effective PrEP care for BMSM would need to be greater or equal to those for WMSM to generate a reduction in the disparity on a relative scale. 
DISCUSSION
In this modeling study, we found that implementation of PrEP could reduce absolute disparities in HIV incidence between BMSM and WMSM even despite current racial gaps in HIV PrEP care. Further disparity reduction with PrEP could be achieved with interventions targeting each of the modeled PrEP continuum steps for BMSM. Major gains in overall HIV incidence reduction and disparity elimination with PrEP would require targeting initiation factors (awareness, access, and prescription) over engagement factors (adherence and retention) for BMSM, given the currently observed PrEP continuum.
Many HIV prevention interventions successful at reducing HIV incidence are challenged by simultaneously addressing persistent HIV racial disparities. Systemic racial gaps in clinical care for testing and treatment of HIV (44) have led to a HIV prevention landscape in which white and higher-income MSM disproportionately benefit (45) . We rooted our model structure and parameters in robust data to estimate how empirical representations of the PrEP continuum could impact HIV incidence over the next decade in a high-burden, low-resource population of younger BMSM (26) . Our model suggests that it is possible to reduce, although not entirely eliminate, disparities in HIV incidence by race while at the same time lowering HIV incidence overall with PrEP.
To guide public health policy, we used a five-step PrEP continuum framework to conceptualize gaps in PrEP care (3) . First, we found that awareness of PrEP was the step most strongly associated with incidence reduction for BMSM, partially due to the marginally declining conditional probabilities for the subsequent steps. Several studies have found reduced interest of BMSM in PrEP (12, 13) , related to lack of knowledge about PrEP and perceived stigma in using it (14, 46, 47) . New technologies, such as mobile phone applications, are currently being developed to address this step. Second, PrEP access given awareness could increase infections averted by 4.1% if raised to observed WMSM levels in our model.
Access-related interventions include patient assistance programs to cover medication costs (48);
however, PrEP requires ongoing monitoring services covered through health insurance, which may be a barrier for some BMSM (15) (16) (17) . Third, we found a relatively minimal effect for prescription rates conditional on access because the observed gap was only 10% (73% versus 63%). While all indicated BMSM seeking a PrEP prescription should receive one, this will depend on indications for PrEP being accurately queried by clinicians who are willing to prescribe PrEP. BMSM are less likely to be "out" to their doctors (49) , and some clinicians may be less willing to prescribe to BMSM than to WMSM (50) . Clinical training on PrEP patient assessment is greatly needed. Fourth, adherence is critical to both the impact and efficiency of PrEP, with a substantial effect on the NNT. Race/ethnicity has been strongly associated with suboptimal PrEP dosing (11, 51) . Long-acting formulations like injectable cabotegravir may benefit BMSM with adherence barriers (52) . Finally, greater retention in PrEP care was strongly associated with both infections averted and lower NNT in our model. PrEP discontinuation for reasons other than lapsed indications has been an increasing challenge in clinical practice as PrEP users mature (53); lessons learned from managing patients with suboptimal levels of retention in HIV medical care may guide considerations of how to limit PrEP discontinuation (3).
We quantified disparities an absolute index that subtracts the standardized incidence rate of WMSM from the BMSM incidence rate, and a relative index that takes their ratio. Many policy documents use the latter: the National HIV/AIDS Strategy, for example, sets a goal to reduce racial disparities in new HIV diagnoses by a relative measure (6) . In a dynamic intervention context, however, we would suggest that ratios are less suitable than differences for three reasons. First, the population-level burden of disease is quantified by the incidence rate of disease per unit of person-time. Using the absolute disparity allows one to express disparities with this same denominator. Second, there are parallels in using the absolute index with the choice of risk differences versus relative risks to quantify public health impact of a risk factor in epidemiological studies (54) . Third, the ratio scale is unstable when the denominator is small relative to the numerator, as it is here. Ratio scales may be misleading for some interventional scenarios in these cases when reducing the difference in the number of incident infections between races has the counterintuitive effect of increasing the disparity ratio. Therefore, we recommend that disparities be quantified as absolute differences. Limitations. Our model conceptualizes racial disparities by simulating a two-race population of MSM of younger non-Hispanic black and white MSM in the Atlanta area. The conclusions drawn from this study are therefore most applicable to this target population. Deviations from random sampling of MSM in this target population from the two network/behavioral studies (11, 21) could have resulted in biases in the estimates of model parameters in these domains. Specifically, because most parameters represent marginal probability and rate estimates, the resulting statistics in our models depend on the specific distribution of covariates in our particular study sample. An overrepresentation of young MSM in these studies, for example, could have resulted in upwardly biased behavioral risk parameters if positively correlated with age. Clinical and biological parameters were drawn from the secondary literature;
aggregating multiple data streams into a single model requires strong assumptions about exchangeability, the implications of which have recently been examined in the methodological literature (55) . However, a related strength of our study with respect to parameterization is its rigorous Bayesian model calibration and validation methods to evaluate and adjust for sources of parameter uncertainty through fitting the model projects to external HIV and STI prevalence and incidence data. Additionally, our model may be limited by the assumption that routine HIV screening is the primary point for entry into PrEP, based on the requirement that HIV testing be performed before PrEP initiation (37) . Initiation of PrEP before specific sexual risk events has also been observed (10) , and our future work will explore variations in reasons for starting PrEP. Finally, the continuum parameters were also based on two studies with race-stratified estimates, and these BMSM study populations may not represent other populations of HIV-uninfected BMSM in the US. Further parameter data are needed for other geographic settings to transport these findings to other MSM populations (56) .
Conclusions. PrEP will play a critical role in HIV elimination in the US, but its success will also depend on how we use it to address the persistent racial disparities in HIV incidence. Implementation of PrEP following a continuum framework could achieve the dual goals of reducing HIV incidence overall and decreasing the disparities in incidence between BMSM and WMSM over the next decade even despite current racial gaps in PrEP care. However, targeting these gaps with existing and novel interventions is greatly needed to make critical advances in using PrEP to reduce disparities. Figure 1 . Empirical distribution of model simulations (n = 250 in each scenario) for race-specific HIV prevalence and HIV incidence (per 100 person-years at risk) at Year 10 for BMSM and WMSM across relative values of the combined BMSM PrEP continuum (awareness, access, prescription, adherence, and retention). Relative value 1.0 is the observed BMSM continuum values, 0.5 is half of those observed, and 2.0 is twice those observed. The vertical dashed line indicates HIV prevalence and incidence among BMSM in the reference "no PrEP" scenario. 
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